ARQL News and Press, ArQule Inc. From 06/03/19

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...

Shares of ArQule (ARQL) have risen by 568% since I initially suggested readers purchase a pilot position due to there being "several ways to win" here. Shares have risen by 81% since my January update piece provided my outlook for 2019, as we looked forward to additional data for BTK inhib...

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019 Healthcare Conference on June 6, 2019 at 11:30 a....

The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...

ArQule, Inc. (Nasdaq: ARQL) today announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20 th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA. The live webcast...

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at the InterCon...

Ovid Therapeutics ( OVID ) has certainly been a poor performer, with shares having fallen by 87% since its IPO priced at $15 in 2017. While the stock initially produced a 75% run up gain since my initial article, it's fallen by more than 80% since my November 2017 update piece. The comp...

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 at 3:15 p.m. PT at the E...

Deals and Financings Everest Medicines II of Shanghai, a company backed by C-Bridge Capital, agreed to pay up to $835 million in upfront and milestone payments for Greater China rights to an Immunomedics (IMMU) antibody-drug conjugate ((ADC)). Sacituzumab govitecan, a clinical stage cand...

Shares of Guardant Health ( GH ) have been on quite a run since its IPO priced at $19 in October of last year. In fact, in just a few short months, the stock was a five bagger at one point in March. The leader in liquid biopsy testing was identified by multiple ROTY members as an intriguing ...